+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients



Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients



Oncotarget 9(12): 10402-10416



We studied the association of the serum levels of the microRNA family members miR-320a/-b/-c with clinico-pathological data to assess their applicability as diagnostic biomarker in prostate cancer (PCa) patients. The levels of miR-320a/-b/-c in 3 groups were evaluated by qRT-PCR (145 patients with PCa, 31 patients with benign prostatic hyperplasia (BPH) and 19 healthy controls). The levels of the three family members of miR-320 were directly correlated within each group (P < 0.001), but they differed significantly among the three groups (P < 0.001). The serum levels of the miR-320 family members were significantly increased in older patients compared to younger patients (≤ 66 years vs. > 66 years, P ≤ 0.001). In addition, the levels of all three miR-320 family members were significantly different in patients with low tumor stage compared with those with high tumor stage (miR-320a: P = 0.034; miR-320b: P = 0.006; miR-320c: P = 0.007) and in patients with low serum PSA compared with those with high serum PSA (≤ 4 ng vs. > 4 ng; miR-320a: P = 0.003; miR-320b: P = 0.003; miR-320c: P = 0.006). The levels of these miRNAs were inversely correlated with serum PSA levels. Detection in the serum samples of PCa patients with or without PSA relapse revealed higher levels of miR-320a/-b/-c in the group without PSA relapse before/after radical prostatectomy than in that with PCa relapse. In summary, the differences among the PCa/BPH/healthy control groups with respect to miR-320a/-b/-c levels in conjunction with higher levels in patients without a PSA relapse than in those with a relapse suggest the diagnostic potential of these miRNA-320 family members in PCa patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 065506889

Download citation: RISBibTeXText

PMID: 29535815


Related references

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer. Biomed Research International 2014: 972587, 2015

Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value in Health 15(5): 716-723, 2012

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Genetics and Molecular Research 15(2), 2017

Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 61(5): 401-408, 2006

Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. European Journal of Nuclear Medicine 26(6): 625-632, 1999

Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL. Clinical Biochemistry 39(4): 363-366, 2006

Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer. Saudi Journal of Kidney Diseases and Transplantation 22(2): 291-297, 2011

Elevated serum levels of human kallikrein 2, free and total PSA many years before diagnosis in patients with prostate cancer. European Urology 39(Suppl 5): 165, 2001

The combination of the KLK2 polymorphism and serum HK2 levels identifies patients with high grade prostate cancer at diagnosis. Journal of Urology 171(4 Supplement): 440, 2004

Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance. World Journal of Urology 36(8): 1209-1217, 2018

Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. Bju International 105(7): 1000-1010, 2010

An e-learning caregiving program for prostate cancer patients and family members. Journal of Medical Systems 27(1): 1-12, 2003

Reliability of highly elevated levels of serum prostate specific antigen in making the diagnosis of prostate cancer. Journal of Urology 165(5 Supplement): 318, 2001

Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients. Hinyokika Kiyo. Acta Urologica Japonica 38(4): 425-431, 1992

Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Journal of Urology 171(1): 182-186, 2003